232 related articles for article (PubMed ID: 31118247)
21. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
[TBL] [Abstract][Full Text] [Related]
22. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
23. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
24. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
25. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
[TBL] [Abstract][Full Text] [Related]
26. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
27. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
28. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
29. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
30. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
31. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
34. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
[TBL] [Abstract][Full Text] [Related]
35. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
36. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
37. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
Qi F; Qin W; Zhang Y; Luo Y; Niu B; An Q; Yang B; Shi K; Yu Z; Chen J; Cao X; Xia J
J Exp Clin Cancer Res; 2021 Sep; 40(1):280. PubMed ID: 34479623
[TBL] [Abstract][Full Text] [Related]
38. microRNA-29a regulates liver tumor-initiating cells expansion via Bcl-2 pathway.
Song S; Sun K; Dong J; Zhao Y; Liu F; Liu H; Sha Z; Mao J; Ding G; Guo W; Fu Z
Exp Cell Res; 2020 Feb; 387(2):111781. PubMed ID: 31857112
[TBL] [Abstract][Full Text] [Related]
39. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
40. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
